Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

Next Previous
Trial Profile

Rituximab in Primary Central Nervous system Lymphoma.A randomized Dutch/Belgian Hemato-Oncology Cooperative Group (HOVON) / Australasian Leukaemia and Lymphoma Group (ALLG) intergroup study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cytarabine; Methotrexate; Prednisolone; Prednisolone; Teniposide
  • Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 105 PCNSL

Most Recent Events

  • 05 Apr 2024 Results (n=199) assessing Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma published in the Neuro-Oncology
  • 02 Aug 2021 Results assessing the effect of treatment on neurocognitive functioning and the association of neurocognition with radiological abnormalities in primary central nervous system lymphoma published in the Neuro-Oncology
  • 01 May 2020 Results assessing impact of rituximab added to standard high-dose methotrexate-based treatment on health-related quality of life, published in the Annals of Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top